---
title: Racial and ethnic differences in clinical outcomes among multiple myeloma patients
  treated with CAR T-cell therapy
date: '2023-10-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37855718/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231019180738&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor
  T-cell therapy to gain FDA approval for patients with relapsed/refractory multiple
  myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially
  and ethnically diverse populations have been understudied. This study pooled data
  from 207 RRMM patients (28% racial and ethnic minority patients) treated with SOC
  ide-cel across 11 institutions to examine racial and ethnic differences in the incidence
  ...
disable_comments: true
---
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain FDA approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 RRMM patients (28% racial and ethnic minority patients) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence ...